Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01719042
Other study ID # 187-2012
Secondary ID
Status Withdrawn
Phase Phase 2
First received October 22, 2012
Last updated April 2, 2013
Start date January 2013
Est. completion date March 2013

Study information

Verified date April 2013
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to improve tolerance of treatment of pulmonary Mycobacterium avium Complex disease via the use of therapeutic drug monitoring and the addition of anti-nausea medication or dietary supplements to the patients' daily drug regimen. The aims of this study are to use (1) Zofran® (Ondansetron 8mg), an anti-nausea medication or (2) a dietary supplement to decrease medication related gastrointestinal side effects of medications used to treat Mycobacterium avium Complex.


Description:

As part of this study, investigators will review medical records to be sure that the patient meets the required criteria and is healthy enough to take part in this study.

The study will consist of five separate visits to the Clinical research Center at the University of Florida and each visit will last anywhere from 6-8 hours. Patients will be given a diary of questionnaires where they will record when they take their medication and any side effects they might have. Patients will also have Electrocardiograms (ECGs) to make sure they are healthy enough to be a participant in the study and to measure the effects of their medication on their heart. During this study, patients will continue treatment of their Mycobacterium avium Complex infections. Patients will be observed taking their medication on each of the five separate days. On each of these days patients will have blood drawn at 2 and 6 hours after their drugs are taken in order to measure drug levels in their blood. We will also use this blood to measure levels of proteins and hormones and to make sure the medications are not affecting the patient's heart. The patient will fill out several questionnaires and do a dietary assessment online. Investigators will assess the patient's body make-up using a device called the Bod Pod. The patient will also be assigned to one of two treatment groups: (1) Ondansetron 8mg (ZofranĀ®, GlaxoSmithKline, Research Triangle Park, NC) every morning before breakfast versus (2) a dietary supplement prior to taking daily medication. The patient will be assigned to the first treatment group for a period of two weeks. On the third study visit investigators will switch the patient to the second group.

Although the incidence of tuberculosis has decreased in the United States over the last few decades, the incidence of chronic pulmonary infections with nontuberculous mycobacteria (NTM) appears to be increasing. Unfortunately, a common problem in the management of these infections is the inability of elderly patients to tolerate the currently recommended multidrug regimen of (1) azithromycin or clarithromycin, (2) rifampin or rifabutin, and (3) ethambutol. The most frequent adverse reactions of MAC treatment are gastrointestinal (GI), most commonly associated with the macrolides and rifampin. Although macrolide toxicity is generally dose-related, the role of routine monitoring of drug concentrations and subsequent dose adjustment has not been studied. The role of anti-emetics or dietary supplements to mitigate these symptoms is also not defined.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2013
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender Female
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Physician diagnosis of Mycobacterium avium Complex with nodular bronchiectasis

- On daily treatment for Mycobacterium avium Complex consisting of 250mg of Azithromycin, 600mg of Rifampin, and 15mg/kg of Ethambutol

- Experiencing gastrointestinal symptoms due to their multi-drug treatment regimen

- Has access to the internet

Exclusion Criteria:

- Claustrophobia

- Currently smokes cigarettes

- Persons with disseminated Mycobacterium avium Complex infections

- Persons with a known and diagnosed immunosuppressive disorder (i.e. cancer, HIV)

- Persons with physician diagnosed Irritable Bowel Syndrome, Crohn's Disease, or Ulcerative Colitis

- Persons with moderate to severe kidney or liver dysfunction

- Persons who are co-colonized with an NTM aside from Mycobacterium avium Complex

- Persons who initially present with a prolonged QT interval (defined as greater 500 milliseconds) on any baseline ECG

- Previous adverse reaction or allergy to Zofran (Ondansetron)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Drug:
Zofran (8mg)
Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
Dietary Supplement:
Ensure
Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Florida

Outcome

Type Measure Description Time frame Safety issue
Other Change in QTc on Electrocardiogram greater than 500 milliseconds To determine if the drug-drug interaction of azithromycin and Zofran (ondansetron) causes significant prolongation of the corrected QT (QTc) interval in this population of older female patients Change from baseline at the end of nine weeks Yes
Primary Change in Gastroparesis Cardinal Symptom Index Score A survey instrument used to assess the severity of patient-reported gastrointestinal symptoms in clinical trials Change from baseline at the end of nine weeks No
Secondary Leptin Leptin is a natural hormone produced by your body's fat cells and acts as a signal which tells your brain you are no longer hungry Baseline No
See also
  Status Clinical Trial Phase
Completed NCT01764126 - Pneumococcal Protein Vaccine Safety and Immunogenicity Trial Phase 1
Completed NCT00696839 - Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side Effects N/A
Completed NCT00361062 - Aggressive Behavior Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) During the First Month of Treatment N/A
Completed NCT00346944 - Health Effects From Removal of Amalgam Restorations in Patients With Symptoms Allegedly Related to Dental Amalgam Phase 4
Recruiting NCT05486923 - Validity and Reliability Evaluation of the PRO-CTCAE for Adult-type Diffuse Gliomas Patients in Chinese Population
Completed NCT01834898 - Safety and Tolerability of Controlled-release Oxycodone on Postoperative Pain in Oncologic Head and Neck Surgery N/A
Completed NCT01041352 - Laryngeal Mask or Endotracheal Tube for Back Surgery in the Prone Position N/A
Recruiting NCT05090384 - Pediatric GVHD Low Risk Steroid Taper Trial Phase 2
Completed NCT02927587 - Optimal TCI Regimen for Sedation of Elderly Undergoing Fiberoptic Bronchoscopy N/A
Completed NCT02162147 - How Safe Are Our Pediatric Emergency Departments? N/A
Completed NCT01471366 - Method of Fish Oil Administration on Patient Compliance N/A
Completed NCT00773942 - Design & Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries N/A
Completed NCT06102577 - Systemic Adverse Effects After Osteopathic Treatment and Vitamin C N/A
Completed NCT01060410 - Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment N/A
Active, not recruiting NCT00445016 - Neurologic Complications in Peripheral Regional Anesthesia - An Evaluation Based on a Standardized Protocol N/A
Active, not recruiting NCT02668016 - Self-Assessment Method for Statin Side-effects Or Nocebo Phase 4
Completed NCT01533792 - Effect of Non-surgical Periodontal Treatment Phase 2
Active, not recruiting NCT05032976 - Korea Comirnaty Post-marketing Surveillance
Recruiting NCT01650272 - Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia Phase 1/Phase 2
Completed NCT01116323 - Emergency Department Crowding in Relation to In-hospital Adverse Medical Events